Pharnext Presents a Business Update Webcast on May 20th, 2020

PARIS, France, 06:00 pm, April 21, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the organization of a webcast to update its shareholders and investors on May 20, 2020 at 6:00pm (CET).


During this webcast, David Horn Solomon, recently appointed Chief Executive Officer, will provide a business overview of Pharnext’s ongoing business strategy.

Technical details to register and connect to this webcast will be shortly available on the company’s website at www.pharnext.com.

This webscast is organized as a replacement of the one initially planned on April 23, 2020.


About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).